2018 Pharmaceutical Trends and 2019 Outlook
After failed repeal of Obamacare in 2017 and again in 2018, the ACA may very well be here to stay. Cost savings on drugs and product growth will have to come from new areas of
After failed repeal of Obamacare in 2017 and again in 2018, the ACA may very well be here to stay. Cost savings on drugs and product growth will have to come from new areas of
By second quarter 2017 fears of what the new President would do to the health care industry had calmed down. No change in the ACA seemed to be imminent and the President had backed off